使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主
Operator
Operator
Please stand by. Good day, everyone, and welcome to the ICN pharmaceutical second-quarter 2002 earnings results conference call. Today's call is being recorded. At this time, for opening remarks and introductions, I would now like to turn the conference over to Mr. Greg Keever, executive vice president, general counsel, and corporate secretary for ICN. Please go ahead, sir.
請稍候。各位早安,歡迎參加 ICN 製藥公司 2002 年第二季財報結果電話會議。本次電話會議將進行錄音。現在進行開場致詞與介紹,我想把電話會議交給 ICN 的執行副總裁、總法律顧問兼公司秘書 Greg Keever 先生。先生,請開始。
Greg Keever - Executive VP, General Counsel, and Corporate Secretary
Greg Keever - Executive VP, General Counsel, and Corporate Secretary
Thank you. I would like to welcome everyone to today's call. Before we begin the call, I would like to read to you the safe harbor statement under the Private Securities Litigation Reform Act of 1995.
謝謝。我想歡迎各位參加今天的電話會議。在我們開始之前,我想向各位宣讀 1995 年《私人證券訴訟改革法》下的安全港聲明。
This presentation contains forward-looking statements that involve risks and uncertainties, including, but not limited to, projections of future sales, operating income, returns on invested assets, regulatory approval processes, competition from generic products, marketplace acceptance of the company's products, and other risks detailed from time to time in the company's Securities and Exchange Commission filings.
本簡報包含前瞻性陳述,涉及風險與不確定性,包括但不限於:未來銷售、營業利益、投資資產報酬的預測、法規核准流程、學名藥競爭、市場對本公司產品的接受度,以及本公司不時於向美國證券交易委員會提交之文件中所詳述的其他風險。
Joining us on the call today are Robert W. O'Leary, ICN's chairman and CEO, Adam Jerney, president, John Giordani, chief financial officer, Mark Taylor, head of North American operations, Phil [Loberg], treasurer, and Winnie Wu, controller. All of whom will be available to answer questions during the Q and A session. And now I will turn over the call to Mr. O'Leary.
今天與會者包括 ICN 董事長暨執行長 Robert W. O'Leary、總裁 Adam Jerney、財務長 John Giordani、北美營運主管 Mark Taylor、財務主管 Phil [Loberg],以及會計主管 Winnie Wu。他們都將在問答環節提供回答。現在我把電話會議交給 O'Leary 先生。
Robert O'Leary - Chairman and CEO
Robert O'Leary - Chairman and CEO
Thank you, Greg. Welcome to all of you joining us on the call this morning. Our aim this morning is to share with you more detail about the second quarter's results, as well as the status of our strategic review, more than we were able to share when we announced our earnings shortfalls last month.
謝謝你,Greg。歡迎各位今天早上加入我們的電話會議。我們今天早上的目標,是與各位分享第二季業績的更多細節,以及我們策略檢討的進度;這些內容將比我們上個月宣布盈餘不如預期時所能分享的更為完整。
While there are clearly issues in the quarter that we will touch on in a minute, it is important to note that ICN had areas of strong performance in the second quarter to display some of the depth of our operations and helped convince us that the long-term prospects of this business is, indeed, sound.
雖然本季確實存在一些問題,我們稍後會提到,但重要的是要注意,ICN 在第二季也有表現強勁的領域,展現了我們營運的深度,並幫助我們相信這項業務的長期前景確實穩健。
And another important take-away that you hope you have this morning, as you will see from the results that we will announce, the second quarter includes onetime charges that address past events but do not really reflect our ongoing operations.
另外,我希望各位今天早上能帶走的一個重要重點是:從我們即將公布的結果可以看到,第二季包含一次性費用,用以處理過去事件,但並不真正反映我們持續性的營運狀況。
North America and Russia were clearly soft, but these regions are getting back on track and our strategic review will help accelerate that process. In spite of this softness, the fundamentals of the business are good and that will give us a solid base upon which to reshape this company in the future.
北美與俄羅斯的表現明顯疲弱,但這些地區正回到正軌,而我們的策略檢討將有助於加速這個過程。儘管短期疲弱,公司的基本面良好,這將為我們未來重塑公司提供穩固的基礎。
There are three main areas that we want to address this morning with respect to the earnings. First, we're going to talk about our results from operations that exclude nonrecurring and extraordinary items. These results represent the ongoing operations of ICN Americas, ICN international, and Ribapharm.
今天早上就盈餘而言,我們想討論三個主要面向。第一,我們將談談排除非經常性與非常項目後的營運結果。這些結果代表 ICN Americas、ICN International 與 Ribapharm 的持續性營運。
Second, we will talk about the details of the significant amount of nonrecurring charges that are flowing through the quarter. The charges must be recorded as a component of operating income, but don't reflect our ongoing operations.
第二,我們將說明本季認列的大量非經常性費用細節。這些費用必須作為營業利益的組成部分入帳,但並不反映我們的持續性營運。
Third, we'll talk about the extraordinary and unusual items that are below the operating line. These items include the gain on the sale of Ribapharm stock, an extraordinary loss from a debt repurchase, and our application of FSAS 142 with respect to the impairment of goodwill that we adopted on schedule and as planned, and that impacted our six-months results.
第三,我們將談談位於營業利益線以下的非常與不尋常項目。這些項目包括出售 Ribapharm 股票的利益、因回購債務而產生的非常損失,以及我們依計畫並按時採用 FSAS 142、就商譽減損所作的處理,該處理影響了我們六個月的累計結果。
Let me move to ongoing operations.
我先談持續性營運。
Let's first address the results of our ongoing operations. As you can see in the release, we reported revenues of 237 million, operating income of 40.7 million, and net income of 16.3 million or 19 cents per diluted share in the second quarter.
我們先來看持續性營運的結果。如各位在新聞稿中所見,我們第二季報告營收 2.37 億、營業利益 4,070 萬、淨利 1,630 萬,或稀釋後每股 0.19 美元。
Again, these results exclude nonrecurring and extraordinary items, and they are in line with the earnings guidance we gave last month.
再次強調,這些結果排除非經常性與非常項目,並且符合我們上個月提供的盈餘指引。
ICN's results were driven largely by Ribapharm, which had a strong contribution to revenues and profits. As you recall, our partner, Schering-Plough, launched its PEG-Intron and Ribavirin combination therapy in October of 2001 and has seen strong sales as a result. These sales in turn resulted in 66 million in royalty revenue for Ribapharm in the second quarter.
ICN 的業績主要由 Ribapharm 帶動,其對營收與獲利貢獻強勁。如各位所知,我們的合作夥伴 Schering-Plough 於 2001 年 10 月推出 PEG-Intron 與 Ribavirin 的合併療法,並因此看到強勁的銷售表現。這些銷售進而使 Ribapharm 在第二季取得 6,600 萬的權利金收入。
In addition, many of you will recall that last year's sales of Ribavirin were somewhat constrained by the warehousing of FC patients ahead of Schering's PEG-Intron Rebetol launch. Ribapharm also has continued to expand upon its research and development efforts in the antiviral and anticancer therapeutic categories.
此外,許多人也記得,去年 Ribavirin 的銷售在某種程度上受到限制,原因是在 Schering 的 PEG-Intron Rebetol 上市前,FC 病患出現通路囤貨(warehousing)現象。Ribapharm 也持續擴大其在抗病毒與抗癌治療領域的研發投入。
Now, Ribapharm will discuss its results in far greater detail in its earnings release and conference call with analysts and investors tomorrow morning.
接下來,Ribapharm 將在其盈餘新聞稿以及明天早上與分析師和投資人的電話會議中,更詳細地討論其業績。
Results for the specialty pharmaceutical business, which includes ICN Americas and ICN international, were not as impressive as we discussed in our previous earnings guidance. However, as I mentioned earlier, there are areas of strength in that business that continue to perform well, and I will point those out in a moment.
至於專科製藥業務(包含 ICN Americas 與 ICN International)的表現,並未如我們在先前盈餘指引中所討論的那樣亮眼。不過,如我先前提到的,該業務中仍有一些持續表現良好的強項領域,我稍後會指出。
Revenues for the specialty pharma business overall were down 2 million, or 1% in the quarter. But reflect different results in different parts of the globe.
專科製藥業務整體營收在本季減少 200 萬,或 1%。但這反映了全球不同地區的結果各異。
Operating income in the quarter for this business was down substantially, 30.3 million, compared to a year ago. The lower operating income principally reflects the decline in sales as well as higher selling expenses and overhead costs.
本季該業務的營業利益較去年同期大幅下降,減少 3,030 萬。營業利益下滑主要反映銷售下降,以及銷售費用與管理間接費用增加。
Our international operations reported an increase in revenues in the quarter of 9.3 million, or 11% over the last year. The revenue improvement for international was led by our operations in western and Central Europe. These regions experienced strength in several products, such as Calcitron for osteoporosis and [inaudible] for cough, as well as active ingredients such as morphine and Nystatin.
我們的國際業務本季營收增加 930 萬,較去年成長 11%。國際營收改善主要由西歐與中歐的營運帶動。這些地區在多項產品上表現強勁,例如用於骨質疏鬆的 Calcitron、用於咳嗽的 [聽不清],以及嗎啡與 Nystatin 等活性成分。
Eastern European revenues in the second quarter were lower than last year, reflecting our decision to stop production in Russia of certain low-margin products and focus on those with higher margins. In addition, we closed down our direct retail distribution channels in favor of existing national wholesalers. We believe these actions were the right strategic steps to take and have already seen significant increases in sales of our top 10 products in Russia as a result.
第二季東歐營收 低於去年,反映出我們決定 停止在俄羅斯生產某些低毛利 產品,並將重心放在毛利較高的產品上。此外,我們關閉了自營零售 配送通路,改由既有的 全國性批發商承接。我們相信這些行動 是正確的策略性步驟,並且 已經看到俄羅斯前 10 大產品的銷售 因此而顯著增加。
As these steps gain momentum, as we move into the last half of the year, we expect to see revenues from Russia return to planned levels by the end of the year.
隨著這些步驟逐步發揮動能,當我們進入 下半年時,我們預期 來自俄羅斯的營收將在 年底前回到計畫水準。
Operating income for international was substantially lower than last year because of the reduced sales in eastern Europe and because of the increased overhead cost for ICN international, due to the establishment of the division's new headquarters in Basel, Switzerland, which added 5.9 million to operating expenses in the quarter.
國際事業的營業利益 較去年大幅下降,原因在於 東歐銷售下滑,以及 ICN 國際部門的管理費用增加,係因 在瑞士巴塞爾設立該事業部新 總部所致,使本季營業費用增加 590 萬。
So overall, international revenue performed well because of strength in western and Central Europe, but operating income was off because of temporary difficulties in eastern Europe, particularly Russia, and Basel overhead costs.
因此整體而言,國際營收表現良好 主要受惠於西歐與中歐的強勁表現, 但營業利益下滑,係因東歐(特別是 俄羅斯)的暫時性困難,以及巴塞爾總部 管理費用所致。
Revenues for ICN Americas declined 11.2 million or 13% in the second quarter primarily due to lower product sales in North America. Operating income was off 52% in the quarter, reflecting the lower sales, as well as increased operating expenses in the photonics business.
ICN 美洲地區第二季營收減少 1,120 萬,或 13%,主要因北美產品銷售較低。本季營業利益 下滑 52%,反映銷售下降, 以及光子(photonics)業務的營運費用增加。
The decline in North America's revenues, in part, reflects reduced shipments of Mestinon in the quarter to reduce inventory levels in anticipation of the possibility of generic competition.
北美營收下滑,部分原因 是本季 Mestinon 出貨量減少, 以降低庫存水位,因應 可能出現學名藥競爭的情況。
To address this issue, we've developed several marketing programs to stem any potential erosion of our franchise. These programs will be targeted toward key market segments, which include physicians, pharmacies and patients, and have as their focus patient safety.
為因應此議題,我們已制定數項 行銷方案,以遏止我們產品線 可能遭受的侵蝕。這些方案將鎖定 關鍵市場區隔,包括 醫師、藥局與病患,並以 病患安全為核心。
In addition, it is our practice to develop improved delivery forms for certain products that face generic competition, and those plans are in the works for Mestinon.
此外,我們一向會為某些 面臨學名藥競爭的產品開發 改良的給藥形式,而 Mestinon 的相關計畫 也正在進行中。
In addition, the decline in revenues reflects the decision on the part of the company to reduce inventories at wholesalers to a level that moves us closer to industry norms in the second quarter. The company began a program to reduce inventories - excuse me - at its U.S. wholesalers. The company managed production, inventory, and wholesale distribution levels in accordance with customer demand. Inventory levels at wholesalers have historically been held at levels that would ensure availability of product while undergoing a series of manufacturing issues and site changes that require the company to operate with higher inventory levels.
此外,營收下滑也反映出 公司在第二季決定將批發商端庫存 降至更接近產業常態的水準。公司啟動了一項計畫以降低 庫存——抱歉——在其美國 批發商端的庫存。公司依據 客戶需求管理生產、 庫存與批發配送水位。批發商端的庫存水位 過去一向維持在 可確保產品供應的水準,因公司歷經一連串製造問題 與廠址變更,導致公司必須 以較高的庫存水位運作。
The level of inventory supply at wholesalers at the end of June approximated the average level in 2001. We expect to significantly reduce those inventories to a level by the end of this year that this company has not seen since 2000. This action is expected to reduce quarterly revenues by 10 to 12 million per quarter, and we expect smaller reductions in the new year in quarterly revenues in 2003, when wholesaler inventories will move much closer to the norms.
截至 6 月底,批發商端的 庫存供應水位約等同於 2001 年的平均水準。我們預期在今年底前 將大幅降低該等 庫存至公司自 2000 年以來未曾見過的水準。此 行動預期將使每季營收 減少 1,000 萬至 1,200 萬,而我們預期 2003 年新年度每季營收的減幅將較小,屆時批發商庫存 將更接近常態水準。
Also, as we have mentioned in our earnings guidance call, our North American operations were negatively impacted by lower than expected revenue from our photonics business which decreased by 2.6 million in the quarter. In addition, operating expenses for this business were 3.8 million higher in the second quarter, which negatively impacted operating income.
另外,如同我們在盈餘 指引電話會議中提到的,我們的北美營運 受到光子業務營收 低於預期的不利影響,本季減少 260 萬。此外, 該業務的營運費用 在第二季增加 380 萬, 對營業利益造成負面影響。
Another positive, in addition to western and Central Europe, is our operations in Latin America, where we posted strong results in the quarter, with revenues up 3 million, or 10% over last year, and operating income up nearly 30%. This, in spite of currency devaluation of 11% in the region. Latin America benefitted from strong product sales in the quarter, particularly our vitamin B injectables, which generated sales growth of 18%.
另一項正面因素,除西歐與 中歐之外,是我們在拉丁 美洲的營運;本季表現強勁, 營收較去年增加 300 萬,或 10%, 營業利益增加近 30%。即便該地區 貨幣貶值 11%。拉丁美洲受惠於本季強勁的 產品銷售,尤其是我們的 維生素 B 注射劑,帶動銷售 成長 18%。
Our Americas business clearly experienced weakness in the U.S. due to our desire to bring wholesaler inventories down, and because of the weakness in the photonics business, but the product portfolio remains strong, generating revenue and cash flow, and Latin America is clearly a strong region for us.
我們的美洲事業顯然在 美國市場出現疲弱,原因在於我們希望降低批發商 庫存,以及光子業務疲弱, 但產品組合仍然強勁,持續帶來營收與現金流, 而拉丁美洲對我們而言顯然是 強勁的區域。
The company's gross margin was off in the quarter, dropping from 59% last year to 56% in the current quarter. The decline is primarily due to the reduction in sales of higher-margin products in North America, which put pressure on the gross margin.
公司本季毛利率下滑, 由去年 59% 降至本季 56%。下滑主要因 北美高毛利產品銷售減少, 對毛利率造成壓力。
General and administrative expenses were higher in the second quarter versus last year, and primarily reflect the costs of our international headquarters facility in Basel, as well as higher corporate expenses, mainly associated with various overseas M and A and tax issues, as well as severance costs.
第二季一般及行政費用 較去年增加,主要 反映我們位於巴塞爾的國際 總部設施成本,以及較高的 公司層級費用,主要與各項 海外併購(M&A)與稅務議題相關,並包含資遣 成本。
Overhead, I should add, is an area of intense focus of the new management and our advisors. While we can't share with you any specific actions until we complete that review, we do believe that there is considerable room for improvement in ICN's overhead and expect to evaluate this area very, very closely and then take decisive action.
我補充一下,管理費用是新管理團隊 與我們顧問高度關注的領域。在完成該項檢視之前 我們無法與各位分享任何具體行動, 但我們確實相信 ICN 的管理費用 仍有相當大的改善空間,並預期將非常、非常仔細地 評估此領域,然後採取果斷行動。
Let's take a step away now for a moment from the ongoing operations of the company and talk about the nonrecurring and extraordinary items in the second quarter.
現在我們先暫時從 公司持續性營運抽離一下,來談談 第二季的一次性與特殊項目。
As you can see in the release, these items were significant, and I want to describe some of the larger items for you.
如同你們在新聞稿中所見,這些項目 影響重大,我想為各位說明其中 幾個較大的項目。
First, the company repurchased 61 million of employee stock options following what was deemed to be a change in control of the company in the stock option agreements. The second largest nonrecurring item was the cash bonus of approximately 48 million paid to ICN executives and board members in connection with the Ribapharm IPO. In addition, the company paid 13 million in investment banking fees related to the Ribapharm transaction, and wrote off previously capitalized IPO costs for ICN international of 18.3 million.
首先,公司在員工股票選擇權協議中 所認定的公司控制權變更發生後, 回購了 6,100 萬的 員工股票選擇權。第二大 一次性項目,是與 Ribapharm IPO 相關,支付給 ICN 高階主管 與董事會成員約 4,800 萬的現金獎金。此外,公司支付了 1,300 萬 的投資銀行費用(與 Ribapharm 交易相關),並沖銷先前資本化的 ICN 國際部門 IPO 成本 1,830 萬。
The latter were costs the company wrote off because of the substantial passage of time since they were initially incurred and was a step the company was advised to take by our auditors, regardless of whether or not we proceed with the spinoff of international operations.
後者為公司沖銷的成本, 因自最初發生至今已經過相當長的時間; 這也是我們的查核會計師建議公司採取的步驟, 不論我們是否繼續推進 國際營運的分拆。
The company also incurred non-cash expenses related to certain incentive compensation costs based on the change of control provisions in the contracts of several senior executives, which totaled 12 million in the quarter.
公司亦認列與若干 高階主管合約中控制權變更條款 所衍生之特定獎勵性薪酬成本相關的 非現金費用,本季合計 1,200 萬。
Finally, the company incurred expenses of 6.3 million related to the recent proxy contest.
最後,公司因近期的委託書爭奪戰而產生了 630萬的相關費用。
Now, all - I want to yeah size all - of the actions I have just described were taken and executed prior to the seating of the new board and the appointment of the new chairman and CEO on June 19th. The items I outlined for you were the largest components of the nonrecurring charges. The remainder of the charges were for the write-off of in-process R and D related to a recent acquisition, other asset write-offs, and severance costs.
現在,我想要概括一下——是的,概括一下——我剛才所描述的 所有行動,都是在6月19日新董事會就任以及 新任董事長兼執行長獲任命之前就已採取並 執行的。我為各位概述的項目,是非經常性費用中 最大的組成部分。其餘費用則來自 與近期收購相關的在研研發(R&D)沖銷、其他資產沖銷,以及資遣 成本。
While these items are not part of our ongoing operations, we are required to include them in operating income. As a result, our operating profit of 40.7 million from operations was reduced by those charges to a loss of 148.5 million in the quarter.
雖然這些項目不屬於我們的持續性 營運,但我們仍被要求將其納入 營業利益中。因此,我們來自營運的 4,070萬營業利益,因上述費用而 在本季被減少至虧損1億4,850萬。
Going below the operating line, you will see that we have also recorded a onetime gain in the quarter for the proceeds from the Ribapharm IPO that totaled 263 million before taxes. In addition, we recorded, on an after-tax extraordinary loss of 26.8 million, or 27 cents per diluted share for the repurchase of debt in the quarter, related to the Ribapharm IPO. As a result of these onetime and extraordinary items, the company reported a net profit for the second quarter of 32.4 million, or 38 cents per diluted share.
在營業利益線以下,您會看到 我們本季也認列了一次性收益,來自Ribapharm首次公開募股(IPO)的 募資款項,稅前合計2億6,300萬。此外,我們亦認列 一項稅後非常損失2,680萬,或 每股稀釋後27美分,係本季與Ribapharm IPO相關的 債務回購所致。由於這些一次性與非常項目, 公司第二季報告淨利3,240萬,或 每股稀釋後38美分。
The last of our unusual items was the application of a recent accounting rule in which we reviewed our goodwill and other intangible assets for impairment. The rule applies to all companies and we adopted it on schedule.
我們最後一項異常項目,是適用 一項近期會計準則;依該準則我們檢視 商譽及其他無形資產是否發生 減損。該準則適用於所有公司,且 我們已按期採用。
As a result of that review, we wrote down these assets by 25.3 million in the quarter, which we were required to do to reflect - required to reflect in our year-to-date results.
根據該次檢視結果,我們在本季將這些 資產減記2,530萬;這是我們必須做的,以反映——必須 反映在我們年初至今的結果中。
Now, let me step back with you and talk just a bit about the strategic review process.
現在,讓我和各位退一步,稍微談一下 策略檢討流程。
As we previously announced, we've initiated a strategic review of the company's operation and business plans going forward. I want to give you an update on where we are with that review.
如我們先前所宣布,我們已啟動 對公司未來營運與 業務計畫的策略檢討。我想向各位 更新目前檢討進度。
We expect to move quickly and decisively through the process, and expect to have more details to share with you within 90 days. Until that time, we are limited on what we can say to you on the expected outcome.
我們預期將快速且果斷地推進 該流程,並預期在90天內 與各位分享更多細節。在此之前, 我們對於 預期結果能對外說明的內容有所限制。
However, we would like to share with you components of the process we are undertaking as we go through the review, so that you can see that we are moving forward Swiftly and how we are proceeding along that path.
不過,我們希望與各位分享 我們在檢討過程中所採取的 流程組成要素,讓各位看到 我們正迅速向前推進,以及我們如何 沿著這條路徑前行。
We announced recently that ICN retained Goldman Sachs and a leading management consulting firm with significant global pharmaceutical experience to assist us in the process, and their input is proving extremely valuable.
我們近期宣布ICN已聘請高盛(Goldman Sachs)以及一家在全球製藥領域具豐富經驗的 領先管理顧問公司 協助我們推進該流程,而他們的意見 證明極具價值。
As we have said, what remains is a 90-day process and we are still in the early stages, but in the first phase of the process, we are assessing profitability and value creation potential across all regions and product assets, and conducting competitive scans in all our key geographic areas, eastern Europe, Argentina, et cetera. And across each product area, dermatological products versus others, et cetera. To assess the likely future value of assets.
如我們所說,這仍是一個90天的流程, 我們仍處於早期階段;但在 第一階段,我們正評估 各地區與各項產品資產的 獲利能力與價值創造潛力,並在所有主要地理區域 進行競爭掃描, 包括東歐、阿根廷等。並且在 各產品領域之間,例如皮膚科產品相對於 其他產品等。以評估資產在未來可能的 價值。
We are also conducting internal benchmarking to determine improvement opportunities in our operations. In the next phase, we expect to develop a set of strategic asset configuration options that are balanced against risks and feasibility analysis, along with specific strategies and operating models for key assets and business units.
我們也在進行內部標竿比較, 以找出營運上的 改善機會。在下一階段,我們預期 將制定一組策略性資產配置 選項,並結合風險與 可行性分析加以權衡,同時針對關鍵資產與 事業單位提出具體 策略與營運模式。
As we approach the final phase, we'll make determinations on the key action steps needed and develop recommendations to the board for an optimal structure for the company in the future.
當我們接近最後階段時,我們將 決定所需的關鍵行動步驟,並 向董事會提出建議,規劃公司未來的 最佳架構。
As we said before, everything is on the table as we go through this process, including the previously planned spinoff of Ribapharm and spinoff of our international operations. We have made no decisions yet, and don't intend to send any signals at this point. However, we feel that it's important that we be as clear and transparent on the process as we possibly can be.
如我們先前所說,在此流程中 一切皆可討論,包括 先前規劃的Ribapharm分拆 以及我們國際營運的分拆。我們 尚未做出任何決定,也不打算在此時 釋放任何訊號。然而,我們認為 盡可能就流程保持清楚與透明 是很重要的。
As material developments occur, we will share them with you.
一旦出現重大進展,我們將 與各位分享。
Let me move now to talk about certain balance sheet components.
接下來我談談資產負債表中的 若干組成項目。
First, cash at the end of June totaled 290 million, which was a slight decline from the balance at the end of 2001, and a decline of 90 million during the quarter.
首先,6月底的現金合計 2億9,000萬,較2001年底的 餘額略為下降,且本季 減少了9,000萬。
Cash inflows in June quarter included the IPO proceeds and royalty receipts. They were more than offset, however, by outflows that primarily included payment for the bond repurchases, bonuses to management for the Ribapharm IPO, stock option purchases, share repurchases, strategic investments, and taxes.
6月季度的現金流入包括IPO 募資款與權利金收入。然而,這些流入 被現金流出所抵銷;流出主要 包括支付債券回購款、 因Ribapharm IPO支付給管理階層的獎金、 股票選擇權購買、 庫藏股回購、策略性 投資,以及稅款。
Accounts receivable at June 30 totaled 256 million, down 11 million from the balance at December 31. Inventory at June 30 was down as well, totaling 158 million. Stockholders' equity increased by 58 million in the year to 869 million at the end of June.
6月30日的應收帳款合計 2億5,600萬,較12月31日的 餘額減少1,100萬。6月30日的存貨也 下降,合計1億5,800萬。股東權益 年初至今增加5,800萬,至6月底達 8億6,900萬。
Now, I know that a number of you will be looking for us to give you some guidance on what to expect for our results for the rest of 2002.
現在,我知道各位當中有不少人會希望 我們提供一些指引,說明 2002年剩餘期間的業績預期。
I must tell you that our strategic review complicates the guidance process to the extent that the outcome of that review affects, of course, the structure of the business going forward.
我必須告訴各位,我們的策略檢討 使得提供指引的流程更為複雜,因為 該檢討的結果當然會影響 未來的業務架構。
But I can tell you that based on the information we have today in our core businesses, that we are not uncomfortable with the consensus estimates that are on the street today for 2002.
但我可以告訴各位,根據我們目前掌握的 核心業務資訊,我們 對於市場目前對2002年的 一致預估(consensus estimates)並不感到不安。
I will forewarn you, however, that our strategic review could significantly alter the assumptions we are using today, which could impact those estimates.
不過我先提醒各位,我們的策略檢討 可能會大幅改變我們目前採用的 假設,進而可能影響 這些預估。
In addition, the outcome of the strategic review could result in the need for the company to record additional nonrecurring charges in the latter half of 2002 that would not be a part of our ongoing operations.
此外,策略檢討的結果 可能導致公司在2002年下半年 需要認列額外的非經常性費用, 而這些費用不會屬於我們的持續性 營運。
I know this has been a challenging quarter for everyone. You can imagine what a welcome it was for me, after only 33 days on the job. While we have experienced weakness in some of our business units, I am now more convinced than ever that our business is fundamentally solid and that our long-term prospects are good. This was clearly evident in our product portfolio and in the business units that performed well, such as western and Central Europe and Latin America.
我知道這對所有人而言都是艱難的一季。各位可以想像, 對我而言,在上任僅33天後就遇到這樣的情況, 是多麼「受歡迎」。雖然 我們在部分事業單位經歷了疲弱, 但我現在比以往任何時候都更確信,我們的 業務基本面穩健,且我們的 長期前景良好。這在我們的產品組合以及 表現良好的事業單位中清楚可見,例如 西歐與中歐,以及拉丁美洲。
Issues that were a part of the second quarter are being actively addressed by management. We've already taken steps to stem potential erosion from generic competition and to reduce wholesaler inventories to a level that moves us closer to the industry norms. The levels of overhead at corporate and international headquarters are areas that we will focus on intently in the weeks ahead, and we expect to move decisively to make corrections.
第二季期間出現的問題 正由管理階層積極處理中。我們 已經採取措施,以遏止來自 學名藥競爭可能造成的侵蝕,並降低批發商 庫存至更接近 產業常態的水準。公司與 國際總部的間接費用水準,是 我們未來幾週將密切聚焦的領域, 並且我們預期將果斷採取行動 進行修正。
We believe that ICN has a solid platform upon which to build and shape this company through our strategic review, and we expect to have much more to say about that in the coming weeks.
我們相信 ICN 擁有穩固的平台, 可供我們透過 策略檢討來建構並塑造這家公司, 而我們預期在未來幾週 將有更多內容可以說明。
With that, I would like to open the call to questions. Please limit your questions to one per person, to allow as many as possible on the call to participate. As we mentioned earlier, several of our officers are here with me or on the phone and will be able to answer your questions. Phil, would you be kind enough to take the first question, please? 00:22:42
接下來,我想開放 問答。請將問題限制為每人一題, 以便讓盡可能多的與會者 參與。如同我們先前提到的,我們有數位 主管與我在現場或在線上 並能回答各位的問題。Phil, 能否請你協助先接第一個 問題? 00:22:42
Operator
Operator
Thank you, Mr. O'Leary. Our question and answer session will be conducted electronically. If you would like to ask a question for our panel of speakers, please firmly press the star key followed by the digit 1 on your touch-tone telephone. We will take the questions as you have signaled us, and take as many questions as time permits. Once again, that is star 1 to ask your question. And we'll pause for just a moment to assemble our roster.
謝謝您,O'Leary 先生。我們的 問答環節將以 電子方式進行。若您想向我們的講者群 提問,請在您的 按鍵式電話上用力按下星號鍵 再按數字 1。我們將依各位發出訊號的順序 接受提問,並在時間允許下 盡可能多回答問題。再次提醒, 提問請按星號 1。我們將稍作停頓, 以整理提問名單。
And our first question comes from Michael Tong with Wachovia Securities.
第一個問題來自 Wachovia Securities 的 Michael Tong。
Analyst
Analyst
Hi. Good morning. Actually, I have a question concerning the international headquarters. A couple of things. One, if I recall correctly, there used to be an international headquarters in Moscow. Have you written that investment down? Is it still there? And two, as it relates to the international headquarters, outside of that extraordinary cost, is there any other things that's in the SG and A line that might be onetime related so we can look forward to what the - what the ongoing SG and A would be like in the next several quarters? Thank you.
嗨。早安。其實,我有 一個關於國際 總部的問題。有幾點。第一,如果我 沒記錯的話,以前在莫斯科 有一個國際總部。你們 是否已對那項投資認列減損?它還在嗎?第二,關於國際 總部,除了那筆一次性的特殊成本之外, 在 SG&A(銷售、一般及行政費用)項目中 是否還有其他可能屬於一次性的內容, 讓我們可以展望—展望未來幾季 持續性的 SG&A 會是什麼樣子?謝謝。
Robert O'Leary - Chairman and CEO
Robert O'Leary - Chairman and CEO
Phil?
Phil?
Phil Loberg - Treasurer
Phil Loberg - Treasurer
Yes. This is Phil [Loberg]. Thank you for the question. The expenses for headquarters are primarily related to Basel. While there's a regional headquarters in Moscow, bosses you will is where the significant activity occurs.
是的。我是 Phil [Loberg]。謝謝 你的提問。總部相關費用 主要與巴塞爾(Basel)有關。雖然在 莫斯科有一個區域總部,但巴塞爾 才是重大活動發生之處。
With regards to other charges sitting in the G and A, we've attempted to break out the significant items in the nonrecurring. For those that are not classified as nonrecurring, they are in continuing operations and we'll provide more visibility to those when we release the 10-Q.
至於其他列在 G&A(一般及行政費用)中的費用, 我們已嘗試將重大項目 於非經常性項目中分拆揭露。至於未 被歸類為非經常性的部分,則屬於持續 營運,並且我們會在發布 10-Q 時 提供更高的透明度。
Analyst
Analyst
Thank you.
謝謝。
Robert O'Leary - Chairman and CEO
Robert O'Leary - Chairman and CEO
Thank you, Michael.
謝謝你,Michael。
Operator
Operator
And our next question comes from Larry Smith with Gerard Klauer.
下一個問題來自 Gerard Klauer 的 Larry Smith。
Analyst
Analyst
Hi. Could you quantify the impact on revenues and cost of goods sold in the second quarter from the inventory situation in the U.S.?
嗨。你們能否量化第二季 因美國庫存狀況 對營收與銷貨成本造成的影響?
And also, could you comment on what you think, at steady state after the inventory situation has run its course, what the gross margins on your business might be?
另外,你們能否評論一下,在庫存狀況 回到穩態並告一段落之後, 你們業務的毛利率 可能會是多少?
And as a - also, what you think a normal SG and A margin might be.
還有—另外,你們認為正常的 SG&A 利潤率可能會是多少。
Robert O'Leary - Chairman and CEO
Robert O'Leary - Chairman and CEO
There's a lot of questions in there, Larry. You sure got your nickel's worth. Let's see which of those we can get to and then there may be some of them we'll want to get back to you off-line on. Phil?
Larry,你這裡面 問了很多問題。你可真是把錢花得很值得。我們看看哪些能先回答, 其中有些可能我們會想 之後私下再回覆你。Phil?
Phil Loberg - Treasurer
Phil Loberg - Treasurer
Yeah, this is Phil [Loberg]. In the quarter just ended, the reduction in inventory was approximately 15 million, and as we indicated, a significant portion of that was related to the effect of a generic entry or potential generic entry, and as it affected our inventory levels in our wholesaler chain.
好的,我是 Phil [Loberg]。在 剛結束的這一季,庫存減少 約 1,500 萬,而如我們所指出的,其中相當一部分與 學名藥進入或潛在進入的影響有關, 並且影響了我們在 批發通路中的庫存水位。
With regards to the remaining quarters of the year, we estimate the range of that impact to be approximately around the $10 million level on the revenue line. And a lesser amount going into next year.
至於今年剩餘季度, 我們估計該影響在 營收端約落在 1,000 萬美元左右的區間。而進入 明年後影響會更小。
With regard to margins, North America has significantly - or has higher margins than the other enter - than the international regions, and as a result, that shortfall in North America has negatively impacted margins, but we expect, as we work off that inventory situation, the margins will continue to restore themselves back to normal levels.
就利潤率而言,北美的利潤率 顯著—或說高於 其他事業—高於國際地區, 因此北美的缺口 對利潤率造成了負面影響;但我們預期,隨著 我們消化這個庫存狀況,利潤率 將持續回升至正常 水準。
Robert O'Leary - Chairman and CEO
Robert O'Leary - Chairman and CEO
On the question of SG and A, Larry, let me just say this: Without pointing to a specific number of benchmark, that's exactly some of the work that we're doing with our consultants now. Suffice to say that our numbers are sufficiently over any benchmark that we might come up with. We've got work to do in this area, and we'll be much more transparent about what we think the benchmark ought to be and the distance we need to travel in future calls, but I think you're right on with the question. I'd like to not be pinned down on a number just yet, but we'll be prepared to be very specific on this next time around.
關於 SG&A 的問題, Larry,我只想這麼說:在不指向 某個特定的基準數字的前提下,這正是 我們目前與顧問正在進行的 一部分工作。簡單來說,我們的數字 明顯高於任何我們可能提出的基準。我們在這個領域 還有很多工作要做;在未來的電話會議中,我們會更透明地說明 我們認為基準應該是多少,以及 我們需要縮小多少差距,但我認為 你的問題切中要點。我希望 目前先不要被釘死在某個數字上,但下次 我們會準備好在這方面給出非常具體的說明。
Analyst
Analyst
Okay. Thank you.
好的。謝謝。
Robert O'Leary - Chairman and CEO
Robert O'Leary - Chairman and CEO
Yeah.
好。
Operator
Operator
We will now hear from Matt Duffy with black diamond research.
接下來我們將聽取 來自 Black Diamond Research 的 Matt Duffy。
Analyst
Analyst
Yes. Good morning. Thank you very much for taking my question. Just wanted to try and get a little clarity on the inventory situation. I think on your last call, you had expected inventory reductions to move into the middle of next year, and today you're just saying that you expect some - some effect through 2003.
是的。早安。非常 感謝讓我提問。我只是想 更釐清一下庫存 的狀況。我記得在你們上次的電話會議中,你們 預期庫存下降會延續到 明年年中,而今天你們只是說 你們預期在 2003 年仍會有—有一些影響。
Can you talk about how far into 2003 you might expect the impact and you see it's less than 10 to 12 million per quarter, but any sense of how low it's going to go?
你們能談談在 2003 年會影響到多後面嗎? 你們說每季影響低於 1,000 萬到 1,200 萬,但能否提供一些概念, 它大概會降到多低?
Robert O'Leary - Chairman and CEO
Robert O'Leary - Chairman and CEO
Matt, you - you listen well. Let me - let me say, in fact, that we think we'll - we're going to make the most significant improvement as we get through the rest of this year. And then we will cut down the pace of improvement as we get into 2003. We are planning at the present time to spread that effect throughout 2003, but it will be nowhere as dramatic on a per-quarter basis as it is in 2002. Meaning the second, third, and fourth quarters. If that helps you at all.
Matt,你——你聽清楚。讓我——讓我說,事實上,我們認為 隨著今年剩餘時間的推進,我們——我們將會做出最顯著的 改善。然後當我們進入2003年時,我們會放慢 改善的步伐。我們目前的規劃是 將那個效果分散在整個2003年,但按每季來看, 它不會像2002年那樣 戲劇性。也就是指第二、第三與第四季。希望這對你多少有幫助。
What I want to do is see where we are at the end of 2002 and then reevaluate the program, but in general, our view is that rather than taking it out in bigger - in the same size chunks in the first quarter or second quarter of 2003, we would be better advised to spread it throughout the year, and that's - that's basically our game plan at this point.
我想做的是先看看我們在2002年底的狀況 然後再重新評估這個計畫,但整體而言, 我們的看法是,與其在2003年第一季或第二季 以更大——或相同大小的區塊一次次拿出來, 我們更應該把它分散到 全年,而那——那基本上就是我們目前的作戰計畫。
Analyst
Analyst
Okay. Thank you very much.
好的。非常感謝。
Operator
Operator
We will now hear from Bill [Pechar] with Aristia capital.
接下來我們將聽取來自Aristia Capital的Bill [Pechar]。
Analyst
Analyst
Hi, guys. Just a couple questions on the cash flow side. What was capex, and license and product acquisition cash expenditures for the quarter?
嗨,各位。就現金流方面有幾個問題。本季的資本支出(capex),以及授權與產品收購的現金支出是多少?
Phil Loberg - Treasurer
Phil Loberg - Treasurer
On the capex, I think that was approximately 10, 15 million. And with regards to acquisition activity, it was approximately 20 - 20, 25 million for the year-to-date and I think it was about 12 million for the quarter.
關於資本支出,我想大約是 1,000萬到1,500萬。至於 收購活動方面,年初至今大約是2,000萬—— 2,000萬到2,500萬,我想 本季大約是1,200萬。
Analyst
Analyst
Great. Thanks.
很好。謝謝。
Robert O'Leary - Chairman and CEO
Robert O'Leary - Chairman and CEO
Okay, Bill, thank you.
好的,Bill,謝謝你。
Operator
Operator
We will now hear from Rick Stover with Arnold financial.
接下來我們將聽取來自Arnold Financial的Rick Stover。
Analyst
Analyst
Good morning.
早安。
Robert O'Leary - Chairman and CEO
Robert O'Leary - Chairman and CEO
Good morning, Rick.
早安,Rick。
Analyst
Analyst
Could you comment on the status of the CEO search and if you've got any sense of what sort of timing is involved there?
你能否評論一下CEO搜尋的進度, 以及你是否對相關時程 有任何概念?
Robert O'Leary - Chairman and CEO
Robert O'Leary - Chairman and CEO
I can't give you any - any notion on timing, and - but I can tell you that the - Korn/Ferry is doing the search and they seem to be making good progress and have reported to the - to the search committee that they have begun to vet a pool of attractive candidates and I would imagine we'll be moving into the second phase of that search in the - in the next several weeks.
我無法給你任何——任何 關於時程的概念,但——不過我可以告訴你 Korn/Ferry正在負責這次搜尋,他們 似乎進展良好,並已向——向搜尋委員會回報 他們已開始審核一批具吸引力的候選人;我 想像我們將在接下來幾週 進入這次搜尋的第二階段。
Understandably, while I'm a member of the search committee, that hasn't been my primary focus right now. I've left that to the other members of the committee and the search consultant.
可以理解的是,雖然我是搜尋委員會的一員, 但那目前並不是我主要的關注重點。我已把這部分交給委員會的其他成員 以及搜尋顧問。
Classically, in these searches, the first - the first period of time is the research side done by the firm, their ability to talk with and attract candidates, and I will say to you that the feedback we're getting is that there is no - no difficulty interesting candidates in this company because of the - the belief that there's some strong fundamentals and nice up side in the company.
傳統上,在這類搜尋中,第一——第一段時間 是由顧問公司進行研究工作,並看他們與候選人 接觸與吸引候選人的能力;我可以告訴你, 我們收到的回饋是,讓候選人對這家公司產生興趣 並沒有——沒有困難,因為——因為大家相信公司 具備一些強勁的基本面,且有不錯的上行空間。
Analyst
Analyst
Thanks.
謝謝。
Operator
Operator
[inaudible] with [Kober] management has our next question.
[聽不清],來自[Kober] Management,接下來由他提問。
Analyst
Analyst
Hello. Do you have any plans to purchase your outstanding debt in the open market?
你好。你們是否有計畫在公開市場 買回你們的流通在外債務?
Robert O'Leary - Chairman and CEO
Robert O'Leary - Chairman and CEO
I'm sorry, I could barely hear you.
抱歉,我幾乎聽不清楚 你說什麼。
Analyst
Analyst
Do you have any plans to make any open-market purchases of the outstanding debt?
你們是否有計畫對流通在外債務 進行任何公開市場買進?
Robert O'Leary - Chairman and CEO
Robert O'Leary - Chairman and CEO
Phil?
Phil?
Phil Loberg - Treasurer
Phil Loberg - Treasurer
Yeah. Thank you for your question. We're always considering the optimal use of our capital, and that activity and others is currently under consideration at the present time.
是的。謝謝你的提問。我們一直在考量資本的最佳運用方式, 目前這項活動以及其他選項 都正在評估之中。
Analyst
Analyst
Thank you.
謝謝。
Operator
Operator
We will now hear from Mark [Schoenbaum] with CIBC World Markets.
接下來我們將聽取來自CIBC World Markets的Mark [Schoenbaum]。
Robert O'Leary - Chairman and CEO
Robert O'Leary - Chairman and CEO
Yes, Mark.
是的,Mark。
Analyst
Analyst
Hi, everybody. Thanks very much for taking my question. Really appreciate it. Can you just comment, we understand you haven't made a decision yet regarding the Ribapharm spinoff but can you kind of take us through what kinds of arguments on both sides you're considering? What would be some reasons for spinning it off, what would be some reasons for not spinning it off and kind of set the stage for maybe the debate that may be going on internally? Thanks very much.
嗨,各位。非常感謝 讓我提問。真的很感激。你能否 簡單評論一下:我們了解你們尚未就Ribapharm分拆 做出決定,但你能否帶我們了解一下 你們正在考量的正反兩面論點?分拆的理由可能有哪些, 不分拆的理由可能有哪些,並且 為我們鋪陳一下內部可能正在進行的 討論背景?非常感謝。
Robert O'Leary - Chairman and CEO
Robert O'Leary - Chairman and CEO
Mark, I got to admit, that's a nice try. I'm not going to comment or speculate about the strategic review or where we're going, and I'm not smart enough to talk you through the answer to those questions without suggesting, even inadvertently, some sort of a bias, so I'm going to take a pass on your question, Mark.
Mark,我得承認,這招 很高明。我不會就策略檢討或我們將往哪裡走 發表評論或臆測,而且我也不夠聰明 能在不暗示——即使是不經意地——某種偏向的情況下 帶你逐一回答那些問題,所以我就不回答你的問題了,Mark。
Analyst
Analyst
I understand. And - that's fair. And in terms of the timing for news on that, could we expect - you mentioned that you would have clarity from the - from the firms - you would finish this process in roughly 90 days. Could we expect clarity as to the spinoff plans in 90 days as well?
我理解。而且——這很公平。那就相關消息的時程而言,你提到 你們會從——從顧問公司那邊得到明確結論——你們 大約會在90天內完成這個流程。那我們是否也可以期待 在90天內對分拆計畫同樣有明確結論?
Robert O'Leary - Chairman and CEO
Robert O'Leary - Chairman and CEO
It would be my strong hope that that would be what we could do. This is the first time we've given you a signal as to the time line here. We're being fairly aggressive with it, but having made a commitment to you, we will do everything humanly possible to meet that, and - and have answers for you on those questions by that time.
我非常希望 我們能做到這點。這是我們第一次向各位釋出 這裡的時間表訊號。我們推進得相當積極, 但既然已對各位做出承諾,我們將 盡一切人力所及來達成,並—— 並在那個時間點前就那些問題 給各位答案。
Analyst
Analyst
Okay. Thanks very much for taking my question.
好的。非常感謝回答我的問題。
Robert O'Leary - Chairman and CEO
Robert O'Leary - Chairman and CEO
Well, thank you, Mark.
好的,謝謝你,Mark。
Analyst
Analyst
Bye-bye.
再見。
Operator
Operator
We will now hear from Bob Dunn with SAM investments.
接下來我們將聽取來自SAM Investments的Bob Dunn。
Analyst
Analyst
Thank you. I was wondering if you could just review - you mentioned most of the items but could you review the major sources and uses of cash during the quarter, and do you have any outlook for cash usage over the rest of the year?
謝謝。我想請問你是否能 簡單回顧一下——你提到了大多數項目,但你能否回顧 本季現金的主要來源與用途,並且你對今年剩餘時間的 現金使用有任何展望嗎?
Robert O'Leary - Chairman and CEO
Robert O'Leary - Chairman and CEO
Certainly. Here's Phil.
當然可以。這裡請Phil回答。
Phil Loberg - Treasurer
Phil Loberg - Treasurer
Yeah. Thank you for your question. The primary inflows for the quarter related, of course, to the IPO proceeds of some 260 million, as well as royalties in the 50s. The outflows for the period primarily special items included the bond repurchase, 230 plus million, the Ribapharm bonuses, approximately 48 million. We had the employee option put of cash out on those was approximately 40 million. We had some share repurchases during the quarter of 32 million. And other acquisitions and activity the remaining balance, bringing us to a balance of cash of 290 million for the quarter.
好的。謝謝你的提問。本季的主要現金流入當然與IPO募資款有關,約2.6億, 以及權利金在5,000多萬。本期的現金流出主要的特殊項目包括 回購債券,2.3億多,Ribapharm 獎金約4,800萬。我們有 員工選擇權賣回(put)所造成的現金流出,約 4,000萬。本季我們也有一些股票 回購,3,200萬。以及 其他收購與活動為剩餘的差額, 使我們本季期末現金餘額 達到2.9億。
Analyst
Analyst
Okay. Thank you. And any outlook for the rest of the year?
好的。謝謝。那麼對今年剩餘時間有任何展望嗎?
Phil Loberg - Treasurer
Phil Loberg - Treasurer
I expect that the cash balances will hold, subject to strategic review and any impacts that that may have. We have some activities which would reduce, in normal course, that are anticipated, but what we don't have considered is any potential activities that would be required by any decisions made as a result of the strategic review.
我預期現金餘額將會維持,惟仍須視策略檢討及其可能帶來的任何影響而定。我們有一些活動在正常情況下會使現金減少,且已在預期之內,但我們尚未納入任何可能因策略檢討所做決策而需要採取的潛在活動。
Analyst
Analyst
Thank you.
謝謝。
Operator
Operator
And just as a reminder, if you'd like to ask a question, please press star 1.
再提醒一次,如果您想提問,請按星號 1。
Moving on, we'll hear from Matt [inaudible] with Quaker capital management.
接下來,我們將聽取來自 Quaker capital management 的 Matt [聽不清]。
Analyst
Analyst
Just a couple more balance sheet numbers. Wondering what, if any, short-term debt you have, what - of all the charges taken in the quarter, are there any remaining that represent a cash obligation, and lastly, do you have - what are your remaining sort of acquisition-related payout obligations.
再問幾個資產負債表的數字。想請教你們是否有任何短期負債;另外,本季認列的各項費用中,是否有任何尚未支付、仍代表現金義務的部分;最後,你們剩餘的、與收購相關的付款義務大概有哪些?
Phil Loberg - Treasurer
Phil Loberg - Treasurer
With regards to our short-term debt, it's immaterial. In terms of the current portion.
關於我們的短期負債,金額不重大。就流動部分而言。
With regards to the remaining cash flows related to extraordinary items, I'd say we're about 70% there.
至於與非常項目相關的剩餘現金流,我會說我們大概已完成 70%。
And with regards to acquisition commitments still pending, it's a nominal amount. 10, 15 million.
至於仍待履行的收購承諾,金額很小,大約 1,000 到 1,500 萬。
Analyst
Analyst
Okay. And that's - so that remaining 30% is of what number?
好的。那麼——剩餘的 30% 是以哪個數字為基礎?
Phil Loberg - Treasurer
Phil Loberg - Treasurer
Of the a hundred and - I think 189 million of special charges.
以那一億——我想是 1.89 億的特殊費用為基礎。
Analyst
Analyst
Okay. So roughly 55 to 60 million to go?
好的。所以大約還有 5,500 到 6,000 萬要支付?
Phil Loberg - Treasurer
Phil Loberg - Treasurer
Actually, a little bit less than that.
其實比那個數字再少一點。
Analyst
Analyst
Okay. And your Q will be filed, I guess, by the 15th?
好的。你們的 10-Q 應該會在 15 號前提交吧?
Phil Loberg - Treasurer
Phil Loberg - Treasurer
That is correct.
沒錯。
Analyst
Analyst
Okay. Thank you.
好的。謝謝。
Operator
Operator
And we do have a follow-up question from Michael Tong.
我們還有 Michael Tong 的追問。
Analyst
Analyst
Hi. Thanks for taking the follow-up.
嗨。謝謝讓我追問。
Could you re- - refresh my memory as to what your exposure in Mexico is, as far as product sales for the Mexican government?
能否請你——幫我回想一下,你們在墨西哥的曝險是什麼情況,特別是對墨西哥政府的產品銷售方面?
Robert O'Leary - Chairman and CEO
Robert O'Leary - Chairman and CEO
Adam?
Adam?
Adam Jerney - President
Adam Jerney - President
Yes. A very good question. As you probably remember, we have discussed the fact, in previous telephonic conferences that we have been concentrating most of our business in the private market sector in Mexico. Therefore, our present exposure, as far as the collection issues is concerned from the government is immaterial.
是的。這是個很好的問題。如你可能記得,我們在先前的電話會議中曾討論過,我們在墨西哥的大部分業務一直集中在民間市場部門。因此,就政府端的收款問題而言,我們目前的曝險並不重大。
Analyst
Analyst
Thank you.
謝謝。
Operator
Operator
And once again, as a reminder, please press star 1 to ask a question.
再次提醒,如欲提問,請按星號 1。
And we do have one question, and that comes from Steven McIntyre with Q investments.
我們有一個問題,來自 Q investments 的 Steven McIntyre。
Analyst
Analyst
Yeah, guys. I just - most of my balance sheet questions have been answered. I just had one on the stock buyback. The Q showed 28 million. I just wanted to make sure, was that last 4 million before the CEO change?
是的,各位。我——我大部分關於資產負債表的問題都已經得到解答。我只有一個關於庫藏股回購的問題。10-Q 顯示 2,800 萬。我只是想確認一下,最後那 400 萬是在 CEO 更換之前回購的嗎?
Phil Loberg - Treasurer
Phil Loberg - Treasurer
That is correct.
沒錯。
Analyst
Analyst
Thanks.
謝謝。
Robert O'Leary - Chairman and CEO
Robert O'Leary - Chairman and CEO
Folks, I guess that concludes our questions. I appreciate - I appreciate them, and hope that this is the last time we sit before you and kind of talk about soft earnings and disappointments. We have talked a little bit about what to look forward in the third and fourth quarter and we will try to make sure we're consistent with - with those expectations. We'll get information to you on the strategic review as - at the earliest opportunity, and we will continue our efforts to improve the clarity, decrease the complexity, and improve the transparency of the company. But as I said earlier, I know that this has been a challenging quarter for everyone, but we believe that this business is fundamentally solid, and that our long-term prospects are good. That should be evident from our product portfolio and the business - and that the business units that have performed well.
各位,我想這就結束我們的問答了。我很感謝——我很感謝大家的提問,也希望這是我們最後一次坐在各位面前談論疲弱的獲利與令人失望的結果。我們已稍微談到第三與第四季可期待的方向,我們會努力確保與——與這些預期保持一致。我們會在最早可行的時點向各位提供策略檢討的資訊,並將持續努力提升清晰度、降低複雜度,並提高公司的透明度。但如我先前所說,我知道這對每個人而言都是艱難的一季,不過我們相信這項業務的基本面仍然穩健,且我們的長期前景良好。這應可從我們的產品組合以及——以及表現良好的事業單位看得出來。
The other thing I would note to you, that the areas that have been problematic in the quarter are the kinds of things that lend themselves quite well to management actions, so there's reasons for optimism about the up side in the future.
另外我想提醒各位,本季出現問題的領域,多屬於相當適合透過管理作為來改善的事項,因此對未來上行仍有樂觀的理由。
The new management team is actively addressing past issues, and we expect to take decisive action in the weeks ahead, as we complete our strategic review.
新的管理團隊正積極處理過去的問題,隨著我們完成策略檢討,我們預期在接下來幾週採取果斷行動。
We believe that ICN has a solid platform on which to build and shape this company, and we look forward to speaking with you about that soon. Thank you all for your time and your questions. Good day.
我們相信 ICN 擁有穩固的平台,可用以打造並塑造這家公司,我們也期待很快能就此與各位交流。感謝各位撥冗與提問。祝各位有美好的一天。
Operator
Operator
Thank you. That does today's conference. Thank you for your participation.
謝謝。今天的電話會議到此結束。感謝各位的參與。